Vonoprazan based dual therapy of H.Pylori infection - Front. Med.,2026

The study titled "Vonoprazan-based dual therapy for H. pylori eradication" published in Frontiers in Medicine in 2026 systematically evaluates the efficacy and safety of Vonoprazan-based high-dose dual therapy (VPZ-HDDT) compared to proton pump inhibitor-based high-dose dual therapy (PPI-HDDT) for Helicobacter pylori (H. pylori) eradication as a first-line treatment. Below is a detailed summary of the study findings, including an explanation of Vonoprazan and the ideal dual therapy for H. pylori eradication.

What is Vonoprazan?

Vonoprazan (VPZ) is a novel potassium-competitive acid blocker (P-CAB) that has emerged as a highly effective acid-suppressing agent. Unlike traditional proton pump inhibitors (PPIs), Vonoprazan exhibits:

• Rapid onset of action: It begins suppressing gastric acid secretion quickly.
• Potent acid inhibition: It provides stronger acid suppression compared to PPIs.
• Long-lasting effect: It maintains a stable, high pH environment in the stomach for an extended period.

These properties make Vonoprazan particularly suitable for enhancing the effectiveness of H. pylori eradication therapies, as adequate acid suppression is critical for the success of such treatments.

What is the Ideal Dual Therapy for H. pylori Eradication?

The ideal dual therapy for H. pylori eradication involves:

1. High-dose acid suppression: To maintain a consistently high gastric pH, which enhances the efficacy of antibiotics.

2. Amoxicillin: A broad-spectrum antibiotic with low resistance rates that targets H. pylori.

3. Simplified regimen: A two-drug regimen (high-dose dual therapy) is preferred over triple or quadruple therapies due to reduced complexity, fewer side effects, and better patient compliance.

Vonoprazan-based high-dose dual therapy (VPZ-HDDT) includes:

• Vonoprazan: Provides potent and stable acid suppression.
• Amoxicillin: Administered at a high dose (3,000 mg/day) to maximize its antibacterial activity.

This dual therapy regimen is designed to improve eradication rates while minimizing adverse effects and ensuring high patient compliance.

Study Summary

• Efficacy: VPZ-HDDT demonstrated superior H. pylori eradication rates compared to PPI-HDDT, making it a more effective first-line treatment option.
• Safety: Both regimens had comparable safety profiles, with no significant differences in adverse event rates.
• Compliance: High compliance was observed in both groups, indicating that patients tolerated both regimens well.

Key Takeaway

Vonoprazan-based high-dose dual therapy (VPZ-HDDT) is a highly effective and safe first-line treatment for H. pylori eradication, outperforming traditional PPI-based dual therapy in terms of eradication rates while maintaining comparable safety and compliance. This novel approach has the potential to become the new standard for H. pylori management.